ArticleJournal of magnetic resonance imaging : JMRI2021
Voxel-level Classification of Prostate Cancer on Magnetic Resonance Imaging: Improving Accuracy Using Four-Compartment Restriction Spectrum Imaging.
Article in Journal of magnetic resonance imaging : JMRI, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Focal radiotherapy boost to MR-visible tumor for prostate cancer: a systematic review.World journal of urology · 2024Pooled it
- Trial protocol: RadTARGET, a multicenter phase II randomized controlled trial evaluating focal radiotherapy boost with de-intensification of dose to non-suspicious prostate in patients with intermediate- or high-risk prostate cancer.Clinical and translational radiation oncology · 2026Article
- The role of diffusion-weighted MRI in biological image-guided radiation therapy: a roadmap.Physics in medicine and biology · 2026Review
- Systematic effects of patient factors and scanner/protocol factors on a Restriction Spectrum Imaging (RSI) quantitative MRI biomarker for prostate cancer.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Deep Learning Artificial Intelligence and Restriction Spectrum Imaging for Patient-level Detection of Clinically Significant Prostate Cancer on Biparametric Magnetic Resonance Imaging.European urology open science · 2026Article
- Current state of the art of new prostate MRI technologies and potential future developments.BJR open · 2026Review
- Histology-informed microstructural diffusion simulations for MRI cancer characterisation-the Histo-μSim framework.Communications biology · 2025Article
- Restriction Spectrum Imaging as a Quantitative Biomarker for Prostate Cancer With Reliable Positive Predictive Value.The Journal of urology · 2025Article
- Toward a Refined PI-RADS: The Feasibility and Limitations of More Informative Metrics in Reviewing MRI Scans.Journal of magnetic resonance imaging : JMRI · 2025Review
- Improved differentiation of prostate cancer using advanced diffusion models: a comparative study of mono-exponential, fractional-order-calculus, and multi-compartment models.Abdominal radiology (New York) · 2025Article
- Narrative review of focal boost to intraprostatic dominant lesion in intensity-modulated radiation therapy for localized or locally advanced prostate cancer.International journal of clinical oncology · 2025Review
- Advanced Restriction Imaging and Reconstruction Technology for Prostate Magnetic Resonance Imaging (ART-Pro): A Study Protocol for a Multicenter, Multinational Trial Evaluating Biparametric Magnetic Resonance Imaging and Advanced, Quantitative Diffusion Magnetic Resonance Imaging for the Detection of Prostate Cancer.European urology open science · 2025Article
- Utility of quantitative measurement of TScientific reports · 2024Article
- Quantitative MRI biomarker for classification of clinically significant prostate cancer: Calibration for reproducibility across echo times.Journal of applied clinical medical physics · 2024Article
- Emerging and anticipated innovations in prostate cancer MRI and their impact on patient care.Abdominal radiology (New York) · 2024Review
- Comparison of synthesized and acquired high b-value diffusion-weighted MRI for detection of prostate cancer.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Article
- ReIGNITE Radiation Therapy Boost: A Prospective, International Study of Radiation Oncologists' Accuracy in Contouring Prostate Tumors for Focal Radiation Therapy Boost on Conventional Magnetic Resonance Imaging Alone or With Assistance of Restriction Spectrum Imaging.International journal of radiation oncology, biology, physics · 2023Article
- Use of focal radiotherapy boost for prostate cancer: radiation oncologists' perspectives and perceived barriers to implementation.Radiation oncology (London, England) · 2023Article
- A Multicompartmental Diffusion Model for Improved Assessment of Whole-Body Diffusion-weighted Imaging Data and Evaluation of Prostate Cancer Bone Metastases.Radiology. Imaging cancer · 2023Article
- Automated Patient-level Prostate Cancer Detection with Quantitative Diffusion Magnetic Resonance Imaging.European urology open science · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundDiffusion magnetic resonance imaging (MRI) is integral to detection of prostate cancer (PCa), but conventional apparent diffusion coefficient (ADC) cannot capture the complexity of prostate tissues and tends to yield noisy images that do not distinctly highlight cancer. A four-compartment restriction spectrum imaging (RSI PURPOSE: To evaluate the slowest diffusion compartment of a four-compartment spectrum imaging model (RSI STUDY TYPE: Retrospective. SUBJECTS: Forty-six men who underwent an extended MRI acquisition protocol for suspected PCa. Twenty-three men had benign prostates, and the other 23 men had PCa. FIELD STRENGTH/SEQUENCE: A 3 T, multishell diffusion-weighted and axial T2-weighted sequences. ASSESSMENT: High-confidence cancer voxels were delineated by expert consensus, using imaging data and biopsy results. The entire prostate was considered benign in patients with no detectable cancer. Diffusion images were used to calculate RSI STATISTICAL TESTS: Voxel-level discrimination of PCa from benign prostate tissue was assessed via receiver operating characteristic (ROC) curves generated by bootstrapping with patient-level case resampling. RSI
resultsRSI DATA
conclusionRSI EVIDENCE LEVEL: 3 TECHNICAL EFFICACY: Stage 2.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.